NCT03700242View on ClinicalTrials.gov

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year

PHASE3CompletedINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

January 19, 2019

Study Completion Date

April 8, 2020

Conditions
Healthy Volunteers (Rabies Immunization)
Interventions
BIOLOGICAL

HDCV

Pharmaceutical form:Solution for injection Route of administration: Intramuscular

BIOLOGICAL

HDCV

Pharmaceutical form:Solution for injection Route of administration: Intradermal

BIOLOGICAL

PVRV

Pharmaceutical form:Solution for injection Route of administration: Intramuscular

BIOLOGICAL

PVRV

Pharmaceutical form:Solution for injection Route of administration: Intradermal

Trial Locations (2)

1770

Investigational Site Number 001, City of Muntinlupa

6000

Investigational Site Number 002, Cebu City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03700242 - Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year | Biotech Hunter | Biotech Hunter